Cornelisse Simone, Fleischer Kathrin, van der Westerlaken Lucette, de Bruin Jan-Peter, Vergouw Carlijn, Koks Carolien, Derhaag Josien, Visser Jantien, van Echten-Arends Jannie, Slappendel Els, Arends Brigitte, van der Zanden Moniek, van Dongen Angelique, Brink-van der Vlugt Janneke, de Hundt Marcella, Curfs Max, Verhoeve Harold, Traas-Hofmans Maaike, Wurth Yvonne, Manger Petra, Pieterse Quirine, Braat Didi, van Wely Madelon, Ramos Liliana, Mastenbroek Sebastiaan
Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, Netherlands
Centre for Fertility, Nij Geertgen, Elsendorp, Netherlands.
BMJ. 2024 Sep 16;386:e080133. doi: 10.1136/bmj-2024-080133.
To evaluate whether embryo transfers at blastocyst stage improve the cumulative live birth rate after oocyte retrieval, including both fresh and frozen-thawed transfers, and whether the risk of obstetric and perinatal complications is increased compared with cleavage stage embryo transfers during in vitro fertilisation (IVF) treatment.
Multicentre randomised controlled trial.
21 hospitals and clinics in the Netherlands, 18 August 2018 to 17 December 2021.
1202 women with at least four embryos available on day 2 after oocyte retrieval were randomly assigned to either blastocyst stage embryo transfer (n=603) or cleavage stage embryo transfer (n=599).
In the blastocyst group and cleavage group, embryo transfers were performed on day 5 and day 3, respectively, after oocyte retrieval, followed by cryopreservation of surplus embryos. Analysis was on an intention-to-treat basis, with secondary analyses as per protocol.
The primary outcome was the cumulative live birth rate per oocyte retrieval, including results of all frozen-thawed embryo transfers within a year after randomisation. Secondary outcomes included cumulative rates of pregnancy, pregnancy loss, and live birth after fresh embryo transfer, number of embryo transfers needed, number of frozen embryos, and obstetric and perinatal outcomes.
The cumulative live birth rate did not differ between the blastocyst group and cleavage group (58.9% (355 of 603) 58.4% (350 of 599; risk ratio 1.01, 95% confidence interval (CI) 0.84 to 1.22). The blastocyst group showed a higher live birth rate after fresh embryo transfer (1.26, 1.00 to 1.58), lower cumulative pregnancy loss rate (0.68, 0.51 to 0.89), and lower mean number of embryo transfers needed to result in a live birth (1.55 1.82; P<0.001). The incidence of moderate preterm birth (32 to <37 weeks) in singletons was higher in the blastocyst group (1.87, 1.05 to 3.34).
Blastocyst stage embryo transfers resulted in a similar cumulative live birth rate to cleavage stage embryo transfers in women with at least four embryos available during IVF treatment.
International Clinical Trial Registry Platform NTR7034.
评估囊胚期胚胎移植是否能提高取卵后的累积活产率,包括新鲜胚胎移植和冻融胚胎移植,以及与体外受精(IVF)治疗中的卵裂期胚胎移植相比,产科和围产期并发症的风险是否增加。
多中心随机对照试验。
荷兰的21家医院和诊所,2018年8月18日至2021年12月17日。
1202名在取卵后第2天至少有4个可用胚胎的女性被随机分配到囊胚期胚胎移植组(n = 603)或卵裂期胚胎移植组(n = 599)。
在囊胚组和卵裂组中,分别在取卵后的第5天和第3天进行胚胎移植,然后将多余的胚胎冷冻保存。分析采用意向性分析,次要分析按方案进行。
主要结局是每次取卵的累积活产率,包括随机分组后一年内所有冻融胚胎移植的结果。次要结局包括新鲜胚胎移植后的累积妊娠率、妊娠丢失率和活产率、所需胚胎移植次数、冷冻胚胎数量以及产科和围产期结局。
囊胚组和卵裂组的累积活产率无差异(58.9%(603例中的355例)对58.4%(599例中的350例);风险比1.01,95%置信区间(CI)0.84至1.22)。囊胚组新鲜胚胎移植后的活产率较高(1.26,1.00至1.58),累积妊娠丢失率较低(0.68,0.51至0.89),活产所需的平均胚胎移植次数较低(1.55对1.82;P<0.001)。囊胚组单胎中中度早产(32至<37周)的发生率较高(1.87,1.05至3.34)。
在IVF治疗期间至少有4个可用胚胎的女性中,囊胚期胚胎移植的累积活产率与卵裂期胚胎移植相似。
国际临床试验注册平台NTR7034。